[
  {
    "ts": null,
    "headline": "AbbVie (NYSE:ABBV) Showcases Promising Phase 1 ADC Results For Advanced Cancers",
    "summary": "AbbVie (NYSE:ABBV) recently unveiled promising data on its investigational therapies, including the novel c-Met-targeting ADC, Temab-A, and the SEZ6-directed ADC, ABBV-706, indicating progress in their clinical pipelines. Despite these announcements, AbbVie's stock price remained flat, aligned with overall market stability. The market awaited significant financial updates, such as Nvidia's anticipated earnings report, contributing to a general holding pattern in stock movements. While...",
    "url": "https://finnhub.io/api/news?id=431c84ec698d4eeee8fee47f65fdbc01410d987a2f894116583a0aa845398742",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748454446,
      "headline": "AbbVie (NYSE:ABBV) Showcases Promising Phase 1 ADC Results For Advanced Cancers",
      "id": 134755808,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE:ABBV) recently unveiled promising data on its investigational therapies, including the novel c-Met-targeting ADC, Temab-A, and the SEZ6-directed ADC, ABBV-706, indicating progress in their clinical pipelines. Despite these announcements, AbbVie's stock price remained flat, aligned with overall market stability. The market awaited significant financial updates, such as Nvidia's anticipated earnings report, contributing to a general holding pattern in stock movements. While...",
      "url": "https://finnhub.io/api/news?id=431c84ec698d4eeee8fee47f65fdbc01410d987a2f894116583a0aa845398742"
    }
  },
  {
    "ts": null,
    "headline": "Sarah Cannon Research Institute Announces Strategic Alliance with AbbVie to Advance Novel Cancer Therapies",
    "summary": "Sarah Cannon Research Institute announced a strategic alliance with AbbVie. The alliance aims to accelerate the development of innovative therapies for patients with cancer through collaborative...",
    "url": "https://finnhub.io/api/news?id=ae9f14fbbcc26ccd547a21385a88dd45a6175c1a7b568bdbb0c49f5e1b04e719",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748451095,
      "headline": "Sarah Cannon Research Institute Announces Strategic Alliance with AbbVie to Advance Novel Cancer Therapies",
      "id": 134760754,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "Sarah Cannon Research Institute announced a strategic alliance with AbbVie. The alliance aims to accelerate the development of innovative therapies for patients with cancer through collaborative...",
      "url": "https://finnhub.io/api/news?id=ae9f14fbbcc26ccd547a21385a88dd45a6175c1a7b568bdbb0c49f5e1b04e719"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock underperforms Wednesday when compared to competitors",
    "summary": "AbbVie Inc. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=a4bf347dd85c89a91971c84697c5d4a90f092d210d22a39f7082b891517ee92c",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748449920,
      "headline": "AbbVie Inc. stock underperforms Wednesday when compared to competitors",
      "id": 134814046,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=a4bf347dd85c89a91971c84697c5d4a90f092d210d22a39f7082b891517ee92c"
    }
  },
  {
    "ts": null,
    "headline": "Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?",
    "summary": "Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finnhub.io/api/news?id=8c7452366157869d8de9276d3e54add4af31a9900287e9f7233d3466ef92d286",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748437215,
      "headline": "Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?",
      "id": 134755809,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",
      "url": "https://finnhub.io/api/news?id=8c7452366157869d8de9276d3e54add4af31a9900287e9f7233d3466ef92d286"
    }
  },
  {
    "ts": null,
    "headline": "Carillon Eagle Growth & Income Fund Q1 2025 Commentary",
    "summary": "The S&P 500 Index concluded the first quarter down 4.3%, marking a turbulent start to 2025 following two years of robust gains.",
    "url": "https://finnhub.io/api/news?id=d50e1aa95264fc5360842dad0869e6d58bbfd215a3ed2d2d46118ac2a01bcb00",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748421720,
      "headline": "Carillon Eagle Growth & Income Fund Q1 2025 Commentary",
      "id": 134741260,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2190009797/image_2190009797.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "The S&P 500 Index concluded the first quarter down 4.3%, marking a turbulent start to 2025 following two years of robust gains.",
      "url": "https://finnhub.io/api/news?id=d50e1aa95264fc5360842dad0869e6d58bbfd215a3ed2d2d46118ac2a01bcb00"
    }
  },
  {
    "ts": null,
    "headline": "Carillon ClariVest Capital Appreciation Fund Q1 2025 Commentary",
    "summary": "At the start of the quarter, the Fund was most overweight the financials and healthcare sectors and most underweight consumer discretionary and materials.",
    "url": "https://finnhub.io/api/news?id=93ae24a42a6eb232eca132bda49e57ca0ed9594b96e3bf11ac729635e0289d92",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748419680,
      "headline": "Carillon ClariVest Capital Appreciation Fund Q1 2025 Commentary",
      "id": 134740870,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1814675033/image_1814675033.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "At the start of the quarter, the Fund was most overweight the financials and healthcare sectors and most underweight consumer discretionary and materials.",
      "url": "https://finnhub.io/api/news?id=93ae24a42a6eb232eca132bda49e57ca0ed9594b96e3bf11ac729635e0289d92"
    }
  }
]